skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 1,322  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Refined by: subject: Diabetes remove Journal Title: Cardiovascular Diabetology remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries
CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries
Material Type:
Article 		Add to My Research

CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries

Cardiovascular diabetology, 2021-07, Vol.20 (1), p.154-154, Article 154 [Peer Reviewed Journal]

2021. The Author(s). ;2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Attribution ;The Author(s) 2021 ;ISSN: 1475-2840 ;EISSN: 1475-2840 ;DOI: 10.1186/s12933-021-01344-0 ;PMID: 34315481

Full text available

Citations Cited by
2
Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy
Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy
Material Type:
Article 		Add to My Research

Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy

Cardiovascular diabetology, 2018-06, Vol.17 (1), p.94-22, Article 94 [Peer Reviewed Journal]

Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2018 ;ISSN: 1475-2840 ;EISSN: 1475-2840 ;DOI: 10.1186/s12933-018-0738-4 ;PMID: 29960584

Full text available

Citations Cited by
3
GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
Material Type:
Article 		Add to My Research

GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Cardiovascular diabetology, 2018-12, Vol.17 (1), p.157-19, Article 157 [Peer Reviewed Journal]

Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2018 ;ISSN: 1475-2840 ;EISSN: 1475-2840 ;DOI: 10.1186/s12933-018-0800-2 ;PMID: 30545359

Full text available

Citations Cited by
4
CLOCK gene variation is associated with incidence of type-2 diabetes and cardiovascular diseases in type-2 diabetic subjects: dietary modulation in the PREDIMED randomized trial
CLOCK gene variation is associated with incidence of type-2 diabetes and cardiovascular diseases in type-2 diabetic subjects: dietary modulation in the PREDIMED randomized trial
Material Type:
Article 		Add to My Research

CLOCK gene variation is associated with incidence of type-2 diabetes and cardiovascular diseases in type-2 diabetic subjects: dietary modulation in the PREDIMED randomized trial

Cardiovascular diabetology, 2016-01, Vol.15 (1), p.4-4, Article 4 [Peer Reviewed Journal]

Copyright BioMed Central 2016 ;cc-by (c) Corella Piquer, Dolores et al., 2016 info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by/3.0/es ;Corella et al. 2016 ;ISSN: 1475-2840 ;EISSN: 1475-2840 ;DOI: 10.1186/s12933-015-0327-8 ;PMID: 26739996

Full text available

Citations Cited by
5
Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trial
Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trial
Material Type:
Article 		Add to My Research

Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trial

Cardiovascular diabetology, 2019-06, Vol.18 (1), p.84-84, Article 84 [Peer Reviewed Journal]

2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2019 ;ISSN: 1475-2840 ;EISSN: 1475-2840 ;DOI: 10.1186/s12933-019-0887-0 ;PMID: 31234885

Full text available

Citations Cited by
6
Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease
Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease
Material Type:
Article 		Add to My Research

Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease

Cardiovascular diabetology, 2023-11, Vol.22 (1), p.319-319, Article 319 [Peer Reviewed Journal]

2023. The Author(s). ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1475-2840 ;EISSN: 1475-2840 ;DOI: 10.1186/s12933-023-02051-8 ;PMID: 37985992

Full text available

Citations Cited by
7
GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs
Material Type:
Article 		Add to My Research

GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs

Cardiovascular diabetology, 2021-09, Vol.20 (1), p.189-189, Article 189 [Peer Reviewed Journal]

2021. The Author(s). ;2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2021 ;ISSN: 1475-2840 ;EISSN: 1475-2840 ;DOI: 10.1186/s12933-021-01366-8 ;PMID: 34526024

Full text available

Citations Cited by
8
Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk
Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk
Material Type:
Article 		Add to My Research

Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk

Cardiovascular diabetology, 2022-01, Vol.21 (1), p.12-12, Article 12 [Peer Reviewed Journal]

2021. The Author(s). ;2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2021 ;ISSN: 1475-2840 ;EISSN: 1475-2840 ;DOI: 10.1186/s12933-021-01429-w ;PMID: 35057807

Full text available

Citations Cited by
9
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
Material Type:
Article 		Add to My Research

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

Cardiovascular diabetology, 2019-06, Vol.18 (1), p.73-73, Article 73 [Peer Reviewed Journal]

2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2019 ;ISSN: 1475-2840 ;EISSN: 1475-2840 ;DOI: 10.1186/s12933-019-0871-8 ;PMID: 31167654

Full text available

Citations Cited by
10
Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease
Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease
Material Type:
Article 		Add to My Research

Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease

Cardiovascular diabetology, 2021-07, Vol.20 (1), p.145-12, Article 145 [Peer Reviewed Journal]

2021. The Author(s). ;2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2021 ;ISSN: 1475-2840 ;EISSN: 1475-2840 ;DOI: 10.1186/s12933-021-01343-1 ;PMID: 34271948

Full text available

Citations Cited by
11
The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus
The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus
Material Type:
Article 		Add to My Research

The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus

Cardiovascular diabetology, 2019-05, Vol.18 (1), p.64-64, Article 64 [Peer Reviewed Journal]

2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2019 ;ISSN: 1475-2840 ;EISSN: 1475-2840 ;DOI: 10.1186/s12933-019-0869-2 ;PMID: 31138195

Full text available

Citations Cited by
12
Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials
Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials
Material Type:
Article 		Add to My Research

Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166,371 participants from 170 randomized controlled trials

Cardiovascular diabetology, 2018-06, Vol.17 (1), p.79-79, Article 79 [Peer Reviewed Journal]

Copyright © 2018. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2018 ;ISSN: 1475-2840 ;EISSN: 1475-2840 ;DOI: 10.1186/s12933-018-0722-z ;PMID: 29871636

Full text available

Citations Cited by
13
Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials
Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials
Material Type:
Article 		Add to My Research

Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials

Cardiovascular diabetology, 2019-06, Vol.18 (1), p.70-70, Article 70 [Peer Reviewed Journal]

2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2019 ;ISSN: 1475-2840 ;EISSN: 1475-2840 ;DOI: 10.1186/s12933-019-0875-4 ;PMID: 31159806

Full text available

Citations Cited by
14
Interaction between smoking and diabetes in relation to subsequent risk of cardiovascular events
Interaction between smoking and diabetes in relation to subsequent risk of cardiovascular events
Material Type:
Article 		Add to My Research

Interaction between smoking and diabetes in relation to subsequent risk of cardiovascular events

Cardiovascular diabetology, 2022-01, Vol.21 (1), p.14-14, Article 14 [Peer Reviewed Journal]

2022. The Author(s). ;2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2022 ;ISSN: 1475-2840 ;EISSN: 1475-2840 ;DOI: 10.1186/s12933-022-01447-2 ;PMID: 35073925

Full text available

Citations Cited by
15
Machine learning in precision diabetes care and cardiovascular risk prediction
Machine learning in precision diabetes care and cardiovascular risk prediction
Material Type:
Article 		Add to My Research

Machine learning in precision diabetes care and cardiovascular risk prediction

Cardiovascular diabetology, 2023-09, Vol.22 (1), p.259-259, Article 259 [Peer Reviewed Journal]

2023. BioMed Central Ltd., part of Springer Nature. ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;BioMed Central Ltd., part of Springer Nature 2023 ;ISSN: 1475-2840 ;EISSN: 1475-2840 ;DOI: 10.1186/s12933-023-01985-3 ;PMID: 37749579

Full text available

Citations Cited by
16
Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
Material Type:
Article 		Add to My Research

Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis

Cardiovascular diabetology, 2019-08, Vol.18 (1), p.112-13, Article 112 [Peer Reviewed Journal]

2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2019 ;ISSN: 1475-2840 ;EISSN: 1475-2840 ;DOI: 10.1186/s12933-019-0916-z ;PMID: 31462224

Full text available

Citations Cited by
17
Plasma metabolite profile of legume consumption and future risk of type 2 diabetes and cardiovascular disease
Plasma metabolite profile of legume consumption and future risk of type 2 diabetes and cardiovascular disease
Material Type:
Article 		Add to My Research

Plasma metabolite profile of legume consumption and future risk of type 2 diabetes and cardiovascular disease

Cardiovascular diabetology, 2024-01, Vol.23 (1), p.38-38, Article 38 [Peer Reviewed Journal]

2024. The Author(s). ;2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2024 ;ISSN: 1475-2840 ;EISSN: 1475-2840 ;DOI: 10.1186/s12933-023-02111-z ;PMID: 38245716

Full text available

Citations Cited by
18
Validation of an early vascular aging construct model for comprehensive cardiovascular risk assessment using external risk indicators for improved clinical utility: data from the EVasCu study
Validation of an early vascular aging construct model for comprehensive cardiovascular risk assessment using external risk indicators for improved clinical utility: data from the EVasCu study
Material Type:
Article 		Add to My Research

Validation of an early vascular aging construct model for comprehensive cardiovascular risk assessment using external risk indicators for improved clinical utility: data from the EVasCu study

Cardiovascular diabetology, 2024-01, Vol.23 (1), p.33-33, Article 33 [Peer Reviewed Journal]

2024. The Author(s). ;2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1475-2840 ;EISSN: 1475-2840 ;DOI: 10.1186/s12933-023-02104-y ;PMID: 38218806

Full text available

Citations Cited by
19
Olive oil consumption, plasma metabolites, and risk of type 2 diabetes and cardiovascular disease
Olive oil consumption, plasma metabolites, and risk of type 2 diabetes and cardiovascular disease
Material Type:
Article 		Add to My Research

Olive oil consumption, plasma metabolites, and risk of type 2 diabetes and cardiovascular disease

Cardiovascular diabetology, 2023-12, Vol.22 (1), p.340-340, Article 340 [Peer Reviewed Journal]

2023. The Author(s). ;2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;The Author(s) 2023 ;ISSN: 1475-2840 ;EISSN: 1475-2840 ;DOI: 10.1186/s12933-023-02066-1 ;PMID: 38093289

Full text available

Citations Cited by
20
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
Material Type:
Article 		Add to My Research

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

Cardiovascular diabetology, 2014-06, Vol.13 (1), p.102-102 [Peer Reviewed Journal]

2014 Zinman et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. ;Copyright © 2014 Zinman et al.; licensee BioMed Central Ltd. 2014 Zinman et al.; licensee BioMed Central Ltd. ;ISSN: 1475-2840 ;EISSN: 1475-2840 ;DOI: 10.1186/1475-2840-13-102 ;PMID: 24943000

Full text available

Citations Cited by

Results 1 - 20 of 1,322  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait